Trials / Unknown
UnknownNCT05376423
To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence
A Randomized, Open-Label, Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | OBI-833/OBI-821 | OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic. |
Timeline
- Start date
- 2022-06-02
- Primary completion
- 2024-12-01
- Completion
- 2025-06-01
- First posted
- 2022-05-17
- Last updated
- 2023-11-15
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05376423. Inclusion in this directory is not an endorsement.